Incyte Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Incyte wird ein jährliches Gewinn- und Umsatzwachstum von 17.3% bzw. 8.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 16.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.3% betragen.

Wichtige Informationen

41.1%

Wachstumsrate der Gewinne

41.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	8.9%
Zukünftige Eigenkapitalrendite	24.3%
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Jun 06

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Sep 15

Incyte wins approval of Pemazyre for rare blood cancer

Aug 26

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

Aug 02

With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Jul 27

Incyte Corp. Should Move Higher (Technical Analysis)

Jul 18

Incyte: Growth Drivers Are Coming

Jun 17

Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures

Apr 14

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:INCY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	5,052	1,240	1,455	1,459	19
12/31/2025	4,557	975	1,199	1,114	21
12/31/2024	4,146	181	219	488	21
6/30/2024	3,857	97	-140	-61	N/A
3/31/2024	3,768	745	791	821	N/A
12/31/2023	3,696	598	449	496	N/A
9/30/2023	3,609	425	566	632	N/A
6/30/2023	3,513	366	698	781	N/A
3/31/2023	3,470	324	561	649	N/A
12/31/2022	3,395	341	892	970	N/A
9/30/2022	3,331	876	711	802	N/A
6/30/2022	3,320	945	665	760	N/A
3/31/2022	3,115	933	609	759	N/A
12/31/2021	2,986	949	568	749	N/A
9/30/2021	2,913	535	543	741	N/A
6/30/2021	2,721	338	450	668	N/A
3/31/2021	2,703	478	569	765	N/A
12/31/2020	2,667	-296	-312	-125	N/A
9/30/2020	2,457	-335	-266	-100	N/A
6/30/2020	2,388	-191	-108	-12	N/A
3/31/2020	2,229	-376	-227	-128	N/A
12/31/2019	2,159	447	633	711	N/A
9/30/2019	2,108	405	589	663	N/A
6/30/2019	2,006	306	476	592	N/A
3/31/2019	1,997	253	392	471	N/A
12/31/2018	1,882	109	263	336	N/A
9/30/2018	1,798	-109	90	163	N/A
6/30/2018	1,729	-102	-66	17	N/A
3/31/2018	1,534	-167	N/A	101	N/A
12/31/2017	1,536	-313	N/A	-93	N/A
9/30/2017	1,419	-155	N/A	91	N/A
6/30/2017	1,306	-154	N/A	133	N/A
3/31/2017	1,226	-107	N/A	34	N/A
12/31/2016	1,106	104	N/A	305	N/A
9/30/2016	1,023	151	N/A	280	N/A
6/30/2016	941	74	N/A	193	N/A
3/31/2016	858	49	N/A	189	N/A
12/31/2015	754	7	N/A	89	N/A
9/30/2015	634	-86	N/A	61	N/A
6/30/2015	644	13	N/A	81	N/A
3/31/2015	581	-33	N/A	53	N/A
12/31/2014	511	-48	N/A	26	N/A
9/30/2014	485	-54	N/A	-30	N/A
6/30/2014	372	-136	N/A	-70	N/A
3/31/2014	374	-101	N/A	-47	N/A
12/31/2013	355	-83	N/A	9	N/A
9/30/2013	372	-21	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: INCYDas prognostizierte Gewinnwachstum (17.3% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: INCYDie Erträge des Unternehmens (17.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: INCYEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: INCYDie Einnahmen des Unternehmens (8.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: INCYDie Einnahmen des Unternehmens (8.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: INCYDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (20.2%)

Incyte Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 74%

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Corporation Provides Earnings Guidance for 2024

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Incyte Corporation Revises Earnings Guidance for the Year 2023

Consensus EPS estimates increase by 21%

Recent updates

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Executive VP & Chief Medical Officer recently sold US$704k worth of stock

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP of Global Medical Affairs recently sold US$1.1m worth of stock

Consensus EPS estimates fall by 74%

Executive VP of Global Medical Affairs notifies of intention to sell stock

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Incyte: The Worst Has Been Avoided

Executive VP & GM of North America recently sold US$1.1m worth of stock

Executive VP & GM of North America notifies of intention to sell stock

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte: A Potential GARP Superstar

Incyte Corporation Provides Earnings Guidance for 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Executive VP & Chief Medical Officer recently sold US$1.4m worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Earnings Guidance for the Year 2023

Consensus EPS estimates increase by 21%

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Price target decreased by 7.5% to US$82.42

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive VP & Chief Scientific Officer exercised options to buy US$287k worth of stock.

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Insider exercised options and sold US$115k worth of stock

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Executive VP & Chief Medical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Knight's affiliate files for Brazilian approval of cancer drug tafasitamab

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia